COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial
COSMIC-311 clinical trial : US biotech company Exelixis has enrolled the first 100 patients in a phase 3 trial called COSMIC-311 for evaluating cabozantinib (CABOMETYX) against placebo in a type of thyroid cancer. The COSMIC-311 trial will feature patients having radioactive iodine-refractory differentiated thyroid cancer who have progressed following up to a couple of vascular […]